CA: A Cancer Journal for Clinicians

Vol. 76, Issue 1 Issue 1 2026
26
Articles

Articles in this Issue

Correction to “Self‐collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline”

Jan 01, 2026 10.3322/caac.70066

Cancer statistics, 2026

Rebecca L. Siegel, Tyler B. Kratzer, Nikita Sandeep Wagle et al. Jan 01, 2026 10.3322/caac.70043

ABSTRACT Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer...

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H. Barcenas et al. Jan 01, 2026 10.3322/caac.70055

ABSTRACT The hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC)...

Correction to “Advances in the noninvasive diagnosis of melanoma—40 years beyond the ABCDs”

Jan 01, 2026 10.3322/caac.70074

Pursuit of precision oncology in the treatment of metastatic hormone receptor–positive breast cancer: Making strides or barely moving?

Ilana Schlam, Ajay Dhakal Jan 01, 2026 10.3322/caac.70060

Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics

Laura V. M. Baum, Kimberly L. Johung, Joanna Gibson et al. Jan 01, 2026 10.3322/caac.70050

Cancer statistics, 2026: Charting a course for a national cancer research agenda

Primo N. Lara, Dawn L. Hershman Jan 01, 2026 10.3322/caac.70061

Advances in the noninvasive diagnosis of melanoma—40 years beyond the ABCDs

Joshua Burshtein, Alexander Witkowski, Danny Zakria et al. Jan 01, 2026 10.3322/caac.70065

Abstract The early detection of cutaneous melanoma is critical to survival outcomes. Because less than one half of melanomas in the United States are diagnosed by dermatologists, the...

PORTEC‐3 trial finds that adjuvant chemoradiotherapy significantly improves 10‐year survival for patients with high‐risk endometrial cancer

Carrie Printz Jan 01, 2026 10.3322/caac.70063

Researchers use pooled analysis to define a cure in colon cancer

Carrie Printz Jan 01, 2026 10.3322/caac.70064

Correction to “Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers”

Jan 01, 2026 10.3322/caac.70070

Global incidence of lip, oral cavity, and pharyngeal cancers: Disparities, determinants, and opportunities for prevention, early detection, and treatment

Fernando Neves Hugo Jan 01, 2026 10.3322/caac.70059

Bridging the cancer divide: Policy and structural solutions for equity in the United States

Mariana Chavez‐MacGregor, Inimfon Jackson Jan 01, 2026 10.3322/caac.70054

American Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2025

Farhad Islami, Gladys Arias, Dongjun Lee et al. Jan 01, 2026 10.3322/caac.70045

Abstract Since 2021, the American Cancer Society has published its biennial report on the status of cancer disparities in the United States. In this 2025 report, the authors provide...

Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 2025

Albert Jang, Yousef Zakharia, Pedro C. Barata Jan 01, 2026 10.3322/caac.70056

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

Rana R. McKay, Sumanta Pal, Wanling Xie et al. Jan 01, 2026 10.3322/caac.70052

Abstract The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequenci...

Hyperbaric oxygen therapy for chronic radiotherapy‐related adverse effects: A clinically focused review

Cas Stefaan Dejonckheere, Lukas Käsmann, Leonard Christopher Schmeel et al. Jan 01, 2026 10.3322/caac.70058

Abstract Radiotherapy is a cornerstone of modern oncologic care, yet its sequelae can significantly impair survivors' quality of life. Chronic radiation‐induced conditions—including...

Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors

Mohamed E. Abdelsalam, Kamran Ahrar, Rahul A. Sheth et al. Jan 01, 2026 10.3322/caac.70051

Abstract Interventional radiology (IR) is a rapidly evolving medical field that combines advanced imaging with minimally invasive techniques for both diagnosis and treatment. Interve...

Maintenance therapy after first‐line therapy for ovarian cancer: Quantitative effectiveness

Susana M. Campos, Jessica DiSilvestro, Stephanie V. Blank Jan 01, 2026 10.3322/caac.70057

Self‐collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline

Rebecca B. Perkins, Andrew M. D. Wolf, Timothy R. Church et al. Jan 01, 2026 10.3322/caac.70041

Abstract This update expands the 2020 American Cancer Society (ACS) cervical cancer screening guideline for average‐risk women and individuals with a cervix who...

Human papillomavirus self‐collection: The long road from scientific evaluation to implementation in screening programs

Nicolas Wentzensen, Armando Baena Jan 01, 2026 10.3322/caac.70047

Screening for cervical cancer

Jan 01, 2026 10.3322/caac.70049

Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022

Harriet Rumgay, Murielle Colombet, Amanda Ramos da Cunha et al. Jan 01, 2026 10.3322/caac.70048

ABSTRACT Cancers of the lip, oral cavity, and pharynx (LOCP) represent a substantial public health challenge worldwide. Using GLOBOCAN national estimates of inci...

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Lingying Wu, Jing Wang, Qingshui Li et al. Jan 01, 2026 10.3322/caac.70042

Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian...

A patient with newly diagnosed breast cancer found to have mosaic <i>TP53</i> likely pathogenic variant

Hetal D. Mistry, MacKenzie R. Adams, Charu Taneja et al. Jan 01, 2026 10.3322/caac.70034

All Issues

Journal Info

Publisher Wiley
ISSN 0007-9235
E-ISSN 1542-4863
Subject Medicine
Language English
View Full Journal Page